Company: JACS-RI
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0001013762-25-000620
Chunk: 1056

Company: Jackson Acquisition Co II
Filing Date: 2025-03-18
Form: 10-K
Item: Item 9B
Chunk 1056
---
,300,000)

    Cash Flows from Financing Activities: 

    Proceeds from sale of Units, net of underwriting discounts paid 
     225,400,000 
  
    Proceeds from sale of Private Placement Units 
     8,400,000 
  
    Payment of offering costs 
     (247,801)
  
    Net cash provided by financing activities 
     233,552,199 

    Net Change in Cash 
     949,366 
  
    Cash - Beginning of period 
     — 
  
    Cash - End of year 
    $949,366 

    Non-Cash Investing and Financing Activities: 

    Offering costs included in accrued offering costs 
    $155,484 
  
    Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares 
    $25,000 
  
    Deferred offering costs paid through promissory note – related party 
    $137,604 
  
    Offering costs paid to prepaid expense 
    $14,099 
  
    Offering costs charged to Additional paid in capital 
    $557,741 
  
    Accretion of Class A ordinary shares to redemption value 
    $10,694,910 

The accompanying notes are an integral
part of these financial statements.

F-6

JACKSON
ACQUISITION COMPANY II 
NOTES TO FINANCIAL STATEMENTS

NOTE
1 — ORGANIZATION AND PLAN OF BUSINESS OPERATIONS

Jackson Acquisition Company II (the “Company”)
is a blank check company incorporated as a Cayman Islands exempted company on September 11, 2024. The Company was incorporated for
the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
one or more businesses (“Business Combination”).

While the Company may pursue an initial business
combination target in any industry or geographic location, the Company intends to focus its search for a target business by concentrating
its efforts in identifying high-quality businesses with a focus on healthcare services, healthcare technology, or otherwise focused on
the healthcare industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the
risks associated with early stage and emerging growth companies.

As of December 31, 2024, the Company had not commenced
any operations. All activity for the period from September 11, 2024 (in